A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial

Article Oncology

A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients

Thomas Yau et al.

Summary: The PACOX regimen showed promising anti-cancer activity and survival advantage in advanced pre-treated HCC patients, with a favorable safety profile. Further phase II/III studies are warranted to confirm these findings.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Article Oncology

Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

Christian Recher et al.

Summary: The study compared the overall survival and complete remission rates of acute myeloid leukemia patients aged 70 years or older receiving intensive chemotherapy and hypomethylating agents. The results indicated that intensive chemotherapy was associated with better long-term survival and complete remission rates compared to hypomethylating agents in older AML patients.

LEUKEMIA (2022)

Add to Collection

Article Hematology

A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial

Mike Dennis et al.

Summary: This study investigated the use of tosedostat in combination with low-dose cytosine arabinoside for older patients with AML who are not candidates for intensive treatment. While some improvements were observed in certain response rates with the addition of tosedostat, overall survival was not significantly affected. The study did not find evidence to support the addition of tosedostat to standard treatment in this patient population.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma

Stephen L. Chan et al.

Summary: The study aimed to evaluate the potential clinical efficacy of PEG-BCT-100 in chemo naive sorafenib-failure HCC patients. The results showed that the drug was well tolerated, and patients with ASS-negative tumors had a longer overall survival.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors

Paul N. M. Cheng et al.

Summary: The study found that BCT-100 is safe and has anti-tumor activities in non-Chinese populations with MM and CRPC, with the optimal biological dose for future clinical phase II studies determined as 2.7 mg/kg weekly. Therapeutic Arginine Depletion was observed in the 1.7 and 2.7 mg/kg/week cohorts where anti-tumor activities were also seen.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer

Peter W. Szlosarek et al.

Summary: The combination of ADI-PEG20 with Pem and Cis was well-tolerated and highly active in ASS1-deficient non-squamous NSCLC, although overall survival was poor. ASS1 loss was co-associated with p53 mutations, suggesting further evaluation of therapies incorporating pegargiminase in ASS1-deficient and treatment-refractory NSCLC.

CANCER MEDICINE (2021)

Add to Collection

Article Hematology